SMA Newsroom

Clinical trialsFeb 23, 2022

Recruitment completed for RAINBOWFISH clinical trial of risdiplam

Following our request to receive important and timely updates on their SMA clinical programme, Roche has informed us that worldwide recruitment has completed for the RAINBOWFISH clinical trial, which investigates the efficacy and safety of risdiplam in infants with pre-symptomatic SMA Type 1. This milestone marks the enrolment of 26 participants from across the globe.

TreatmentsClinical trialsDec 16, 2021

Roche provides us with a summary of 2021 activities

Following our request for regular updates, Roche has shared an overview of their work in the community over the past year and a summary of progress in advancing research and increasing access to risdiplam in Europe and beyond.

Clinical trialsOct 22, 2021

Roche to start MANATEE, a global combination study in early 2022

In response to our request, Roche is pleased to inform us about the initiation of MANATEE, a new global Phase 2/3 clinical study to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody targeting muscle growth in combination with risdiplam in SMA.